NXTCL — NextCell Pharma AB Share News
0.000.00%
Last trade - 00:00- SEK126.39m
- SEK94.06m
- SEK13.70m
Brief: Nextcell Pharma Carries Out Rights Issue Of Units
Brief: Nextcell Pharma Says Single Treatment With Protrans Shows Effect Over 5 Yrs
Brief: Hans-Peter Ekre Was Elected New Chairman in Nextcell Pharma
Brief: Nextcell Pharma Resolves On Rights Issue Of SEK 40.1 Mln
Brief: NextCell Pharma Q2 EPS SEK -0.29
Brief: Nextcell Pharma Q2 Oper Loss Narrows To SEK 10.1 Mln
Brief: NextCell Pharma's Chairman Resigns Due To Health Reasons
Brief: Swedish Medical Products Agency Approves Subgroup Analysis In NextCell's ProTrans-Young Study
Brief: Nextcell Pharma To Implement Strategic Changes
Brief: Nextcell Pharma Q1 Operating Loss Widens To SEK 9.8 Mln
Brief: NextCell Pharma Q1 EPS SEK -0.28
Brief: NextCell Pharma Q4 EPS at SEK -0.25
Brief: Nextcell Signs Agreement For New Tissue Product
Brief: Nextcell Pharma Q3 Oper Loss Widens To SEK 10.9 Mln
Brief: Nextcell Pharma Q2 Oper Loss Widens To SEK 11.4 Mln
Brief: NextCell Pharma Q1 Operating Income Rises To SEK 3.0 Mln
Brief: Nextcell Pharma Q4 Oper Loss Widens To SEK 8.6 Mln
Brief: Nextcell Pharma Updates On ProTrans Cell Therapy
Brief: NextCell Pharma: Protrans Cell Therapy Maintains Insulin Production Effect 3.5 Years After Treatment